RCS - Spectral MD Holdings - Appointment: V.P of Marketing

Spectral MD HoldingsAnnouncement

13/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220413:nRSM1932Ia&default-theme=true

RNS Number : 1932I  Spectral MD Holdings, Ltd.  13 April 2022

13 April 2022

 

Spectral MD Holdings, Ltd

("Spectral MD" or the "Company" or the Group")

 

Appointment of Christine Marks as Vice President of Marketing and
Commercialisation

 

Seasoned marketing & commercialisation professional to help bolster
commercialisation expertise

 

LONDON, U.K AND DALLAS, TX, U.S. Spectral MD Holdings, Ltd. (AIM: SMD), a
predictive analytics company that develops proprietary AI algorithms and
optical technology for faster and more accurate treatment decisions in wound
care, announces the appointment of Christine Marks as VP of Marketing and
Commercialisation with immediate effect.

 

Ms. Marks brings over 20 years of marketing and commercialisation experience
to Spectral MD, launching innovations globally at medical device and
technology companies. Ms. Marks is an innovative and strategic marketing
executive with leadership experience in the medical device, diagnostic, B2B
and B2C industries. In addition, Ms. Marks has a successful track record of
driving organisational growth through VOC market research, product launch,
digital companions and building high performing teams. Ms. Marks has been
responsible for transformational commercialisation at high growth companies,
where she was responsible for developing and executing key marketing
strategies and campaigns.

 

Prior to joining Spectral MD, Ms. Marks has held senior marketing roles across
various medical device and technology companies where she has demonstrated
ability to increase revenue, brand value, profit, and marketing ROI.  Most
recently, Ms. Marks served as Vice President, Sales & Marketing at Monarch
Medical Technologies, the maker of the EndoTool
(https://monarchmedtech.com/endotool-glucose-management/) (®
(https://monarchmedtech.com/endotool-glucose-management/) ) Glucose
Management System (https://monarchmedtech.com/endotool-glucose-management/) ,
where she created account-based marketing strategies outlining focused growth
plans and targeted messaging to health systems. Prior to Monarch Medical
Technologies, Ms. Marks has held multiple Vice President of Marketing roles in
the wound care space, where she has been instrumental in developing successful
go-to-market strategies to fuel commercialisation and growth. This experience
in the wound care sector will provide a valuable addition to Spectral MD's
leadership team as it develops its DeepView® wound imaging platform towards
commercialisation.

 

As VP of Marketing and Commercialisation at Spectral MD, Ms. Marks will
develop and implement cohesive marketing plans to increase brand awareness,
while overseeing marketing strategies and efforts to strengthen Spectral MD's
market position and achieve commercial goals.

 

Wensheng Fan, CEO of Spectral MD Holdings, Ltd, said: "We are pleased to
strengthen our commercialisation expertise with the addition of Christine to
our leadership team. With more than 20 years of experience in healthcare
sales, marketing, and commercialisation, Christine will be instrumental in
solidifying our marketing and commercialisation strategy as we work towards
commercialisation and beyond."

 

"Our continued growth has allowed us to bring these experienced leaders to the
company. Christine's expertise is just what we need to scale our growth and
position DeepView(®) for market success."

 

Christine Marks, VP of Marketing and Commercialisation, said: "I am thrilled
to be joining an amazing company and a tremendously talented team at such an
exciting and transformational time. Spectral MD is a pioneer of disruptive
technology that will significantly improve the wound care sector for patients,
and I look forward to further elevating the value of this transformative
technology."

 

For further information please contact:

 

 Spectral MD Holdings, Ltd.                                                           investors.spectralmd.com
 Wensheng Fan, Chief Executive Officer                                                via Walbrook PR
 Nils Windler, Chief Financial Officer

 SP Angel Corporate Finance LLP (NOMAD and Joint Broker)                              Tel: +44 (0)20 3470 0470
 Stuart Gledhill/Caroline Rowe (Corporate Finance)

 Vadim Alexandre/Rob Rees (Sales & Broking)

 Stifel Nicolaus Europe Limited (Joint Broker)                                        Tel: +44 (0) 20 7710 7600

 Charles Hoare / Ben Maddison / Nick Harland / Will Palmer-Brown

 Walbrook PR Ltd (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or spectralMD@walbrookpr.com
 Paul McManus / Sam Allen                          Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

 Alice Woodings                                    +44 (0)7407 804 654

 

 

About Spectral MD:
 

We are a dedicated team of forward-thinkers striving to revolutionize the
management of wound care by "Seeing the Unknown" ® with our DeepView(® )
Wound Imaging System.

www.spectralmd.com

info@spectralmd.com

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAFLAFSSAEAA